ZimVie (ZIMV) Stock Price, News & Analysis

Company Overview

ZimVie, Inc. (NASDAQ: ZIMV) is a global dental solutions company focused on the research, development, manufacturing and commercialization of dental implants, restorative components, digital dentistry platforms and surgical instruments. Formed in April 2022 as a spin-off from Zimmer Biomet, ZimVie combines a heritage of orthopedic and dental innovation with a dedicated focus on meeting the evolving needs of dental professionals. The company’s offerings span implant systems, biologics, prosthetics and regenerative materials designed to support a comprehensive patient care continuum—from diagnostics and treatment planning to post-operative care.

ZimVie’s product portfolio includes endosseous dental implants in a variety of designs and surface technologies, abutments and prosthetic components, guided surgery tools, bone grafting materials and soft tissue management solutions. The company has also invested in digital workflow platforms that enable clinicians to plan implant placement virtually, fabricate custom prosthetics and monitor patient outcomes. By integrating hardware, software and biologic solutions, ZimVie aims to simplify clinical workflows, enhance procedural predictability and improve patient experiences.

Headquartered in Palm Beach Gardens, Florida, ZimVie operates a network of manufacturing, research and distribution facilities across North America, Europe, Asia Pacific and Latin America. Its global footprint supports direct and partner-based sales channels, delivering products and services to dental practitioners, laboratories and healthcare institutions. Since its launch, the company has leveraged its legacy in medical device manufacturing to expand into emerging markets and pursue strategic partnerships that accelerate product innovation and market penetration.

Under the leadership of President and Chief Executive Officer Bryan Hanson, ZimVie is guided by a management team with extensive experience in dentistry, medical technology and life sciences. The company maintains a strong commitment to research and development, investing in clinical studies, digital innovation and regenerative science. As ZimVie continues to build on its heritage, it remains focused on delivering solutions that address both current clinical needs and the future of restorative and regenerative dentistry.

Key Stats

• Today's Range: $8.60 to $8.81
• 50-Day Range: $8.28 to $10.24
• 52-Week Range: $8.15 to $22.40
• Volume: 14,271 shs
• Average Volume: 186,450 shs
• Market Capitalization: $237.92 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.33
• Consensus Rating: Moderate Buy

ZimVie Stock Analysis - MarketRank™

ZimVie scored higher than 45% of companies evaluated by MarketBeat, and ranked 622nd out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

ZimVie has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

ZimVie has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of ZimVie is -12.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ZimVie is -12.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ZimVie has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

20.82% of the float of ZimVie has been sold short.

Short Interest Ratio / Days to Cover

ZimVie has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ZimVie has recently increased by 4,620.90%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ZimVie does not currently pay a dividend.

Dividend Growth

ZimVie does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

20.82% of the float of ZimVie has been sold short.

Short Interest Ratio / Days to Cover

ZimVie has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ZimVie has recently increased by 4,620.90%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 1.19

News Sentiment

ZimVie has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for ZimVie this week, compared to 2 articles on an average week.

MarketBeat Follows

Only 1 people have added ZimVie to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ZimVie insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.01% of the stock of ZimVie is held by insiders.

Percentage Held by Institutions

95.63% of the stock of ZimVie is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ZIMV Stock Analysis - Frequently Asked Questions

How have ZIMV shares performed this year?

ZimVie's stock was trading at $13.95 at the beginning of 2025. Since then, ZIMV stock has decreased by 38.8% and is now trading at $8.5430.

How were ZimVie's earnings last quarter?

ZimVie Inc. (NASDAQ:ZIMV) issued its earnings results on Thursday, May, 8th. The company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.21 by $0.06. The firm had revenue of $112 million for the quarter, compared to the consensus estimate of $113.10 million. ZimVie had a positive trailing twelve-month return on equity of 5.53% and a negative net margin of 4.40%.
Read the conference call transcript.

Who are ZimVie's major shareholders?

ZimVie's top institutional investors include Wealth Enhancement Advisory Services LLC (0.06%). Insiders that own company stock include Camber Capital Management Lp, Vafa Jamali and Richard Heppenstall.
View institutional ownership trends.

How do I buy shares of ZimVie?

Shares of ZIMV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ZimVie own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ZimVie investors own include Chevron (CVX), Comcast (CMCSA), Bristol Myers Squibb (BMY), McKesson (MCK), Charles Schwab (SCHW), Edwards Lifesciences (EW) and Yum! Brands (YUM).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 8/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:ZIMV
• CIK: 1876588
• Web: www.zimvie.com
• Phone: 303-443-7500
• Fax: N/A
• Employees: 1,770
• Year Founded: N/A

Price Target and Rating

• Average Price Target for ZimVie: $16.33
• High Price Target: $23.00
• Low Price Target: $10.00
• Potential Upside/Downside: +91.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.71)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 14.24
• P/E Growth: N/A
• Net Income: -$25.83 million
• Net Margins: -4.40%
• Pretax Margin: -3.55%
• Return on Equity: 5.53%
• Return on Assets: 2.84%

Debt

• Debt-to-Equity Ratio: 0.58
• Current Ratio: 2.14
• Quick Ratio: 1.48

Sales & Book Value

• Annual Sales: $449.75 million
• Price / Sales: 0.53
• Cash Flow: $1.82 per share
• Price / Cash Flow: 4.69
• Book Value: $13.83 per share
• Price / Book: 0.62

Miscellaneous

• Outstanding Shares: 27,850,000
• Free Float: 27,009,000
• Market Cap: $237.92 million
• Optionable: Optionable
• Beta: 2.07